Free Trial

Biotricity Q1 2024 Earnings Report

Biotricity logo
$0.35 +0.03 (+9.53%)
As of 04/3/2025 02:26 PM Eastern

Biotricity EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.34
One Year Ago EPS
N/A

Biotricity Revenue Results

Actual Revenue
$3.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biotricity Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

Biotricity Earnings Headlines

H.C. Wainwright Sticks to Their Hold Rating for Biotricity (BTCY)
Biotricity expands IP portfolio with 14 new patents
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Biotricity reports Q3 EPS (5c) vs. (34c) last year
See More Biotricity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biotricity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biotricity and other key companies, straight to your email.

About Biotricity

Biotricity (OTCMKTS:BTCY), a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

View Biotricity Profile

More Earnings Resources from MarketBeat